609. Acute Kidney Injury during Treatment with Intravenous Acyclovir (AKITA) for Suspected Neonatal Herpes Simplex Virus Infection
Session: Poster Abstract Session: Maternal-Child Infections
Thursday, October 4, 2018
Room: S Poster Hall
Posters
  • AKITA_IDWEEKPOSTER_OCT18_FINAL_092518.pdf (695.3 kB)
  • Background: Intravenous (IV) acyclovir is often administered empirically in neonates with suspected herpes simplex virus (HSV) disease. Acute kidney injury (AKI) can occur within 1-2 days after starting acyclovir due to crystal nephropathy, but the epidemiology of acyclovir-associated AKI in infants is not well-described. Our objective was to detail the incidence and timing of AKI among acyclovir-exposed infants.

    Methods: We identified all hospitalized infants age <60 days treated with ≥1 dose of IV acyclovir for suspected or confirmed neonatal HSV disease from Jan 2011 to Dec 2015 at four U.S. hospitals. Subjects were included if they had both a baseline (lowest value obtained before initiation of acyclovir) and follow-up serum creatinine (SCr; obtained after at least one dose of acyclovir [day 0] through 48 hours after completion) recorded. Infants with congenital kidney disease were excluded. We defined AKI using Kidney Disease: Improving Global Outcomes SCr criteria: ≥50% increase from baseline, or ≥0.3 mg/dL change within any 48-hour period.

    Results: We identified 3374 infants who received IV acyclovir, 1535 of whom (45.5%) had SCr as defined for inclusion in our analyses (range 52-898 infants per hospital); 50% were white, 44% were female, and the median gestational age was 37 weeks (IQR 35 – 39). On acyclovir day 0, the median age was 6 days (IQR 2-18), and 50.0% (n=768) were admitted to the NICU. The median acyclovir dose was 59.5 mg/kg/day (IQR: 55.8-61.2) and the median duration of treatment was 3 days (IQR: 3-6). 32 infants had confirmed HSV disease (10 CNS, 14 disseminated, and 8 skin, eye, and mucous membrane disease). In all, 96 infants (6.3%) had AKI detected after acyclovir initiation including 62 (64.5%) on day 0, 20 (20.8%) on days 1 or 2, and 14 (14.6%) on/after day 3. Of those with AKI on day 1 or later, 41% (n=14) had stage 2 AKI (doubling of SCr or more from baseline). 7 of 32 (21.8%) infants with confirmed HSV had AKI including 4 on day 0, 2 on days 1-2, and 1 on day 12.

    Conclusion: The incidence of AKI among infants treated with IV acyclovir in our study was low. Most AKI was detected soon after acyclovir initiation, potentially owing to more severe illness at the start of treatment and/or drug toxicity, but AKI also developed later. SCr monitoring should be considered throughout acyclovir treatment in infants.

    Brittany L. Haltzman, MS, MPH, CCRC1, Kevin J. Downes, MD1, Susan E. Coffin, MD, MPH, FSHEA, FPIDS1, Kellie M. Liston, MSc1, Hannah M. Emerson, MPH1, Edwin Doe, MD2, Rosanna Fulchiero, DO2, Van Tran, PharmD, BCPPS, BCPS, MBA2, Phuong Lieu, PharmD3, Lilly Yen, PharmD3, Sara L. Van Driest, MD, PhD4, Alison G. Grisso, PharmD, BCPPS5, Ida Aka, MPH4, Jennifer Hale, PharmD, MPA, BCPPS5, Jessica Gillon, PharmD, BCPS5, Julie Pingel, PharmD, BCPPS5, Diqiong Xie, PhD6, Gerold Wharton, MS7 and Ann McMahon, MD, MPH8, (1)Division of Infectious Disease, Children's Hospital of Philadelphia, Philadelphia, PA, (2)Neonatal Intensive Care, Inova Children's Hospital, Falls Church, VA, (3)Children's Hospital Los Angeles, Los Angeles, CA, (4)Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, (5)Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, TN, (6)Food and Drug Administration, Silver Spring, MD, (7)Office of Pediatric Therapeutics, Food and Drug Administration, Silver Spring, MD, (8)Food and Drug Administration, Rockville, MD

    Disclosures:

    B. L. Haltzman, Pfizer, Inc.: Study Coordinator , Salary .

    K. J. Downes, Pfizer, Inc.: Investigator , Research support . Merck, Inc.: Investigator , Research support .

    S. E. Coffin, Merck, Inc.: Investigator , Research support .

    K. M. Liston, None

    H. M. Emerson, None

    E. Doe, None

    R. Fulchiero, None

    V. Tran, None

    P. Lieu, None

    L. Yen, None

    S. L. Van Driest, None

    A. G. Grisso, None

    I. Aka, None

    J. Hale, None

    J. Gillon, None

    J. Pingel, None

    D. Xie, None

    G. Wharton, None

    A. McMahon, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.